Open Access
| Issue |
Med Sci (Paris)
Volume 36, Number 1, Janvier 2020
|
|
|---|---|---|
| Page(s) | 12 - 15 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2019253 | |
| Published online | 04 February 2020 | |
- The Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993 ; 72 : 971–983. [CrossRef] [PubMed] [Google Scholar]
- Vonsattel JP Myers R H Stevens TJ et al. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 1985 ; 44 : 559–577. [CrossRef] [PubMed] [Google Scholar]
- Ross CA Tabrizi SJ Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011 ; 10 : 83–98. [CrossRef] [PubMed] [Google Scholar]
- Roze E Saudou F Caboche J Pathophysiology of Huntington’s disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008 ; 21 : 497–503. [CrossRef] [PubMed] [Google Scholar]
- Karasinska JM Hayden MR Cholesterol metabolism in Huntington disease. Nat Rev Neurol 2011 ; 7 : 561–572. [CrossRef] [PubMed] [Google Scholar]
- Leoni V Mariotti C Tabrizi SJ et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease. Brain 2008 ; 131 : 2851–2859. [CrossRef] [PubMed] [Google Scholar]
- Valenza M Chen JY Di Paolo E et al. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington’s disease in mice. EMBO Mol Med 2005 ; 7 : 1547–1564. [Google Scholar]
- Boussicault L Alves S Lamaziere A et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease. Brain 2016 ; 139 : 953–970. [CrossRef] [PubMed] [Google Scholar]
- Kacher R Lamaziere A Heck N et al. CYP4A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington’s disease. Brain 2019 ; 142 : 2432–2450. [CrossRef] [PubMed] [Google Scholar]
- Hudry E Van Dam D Kulik W et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol Ther 2010 ; 18 : 44–53. [CrossRef] [PubMed] [Google Scholar]
- Durr A. Thérapie par ARN anti-sens dans la maladie de Huntington : un immense espoir et beaucoup d’inconnues. Med Sci (Paris) 2019 ; 35 : 834–836. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.